Aclaris Therapeutics Stock Analysis
| ACRS Stock | USD 1.70 0.10 6.25% |
Aclaris Therapeutics is fairly valued with Real Value of 1.65 and Target Price of 10.0. The main objective of Aclaris Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Aclaris Therapeutics is worth, separate from its market price. There are two main types of Aclaris Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Aclaris Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Aclaris Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Aclaris Stock trading window is adjusted to America/New York timezone.
Aclaris |
Aclaris Stock Analysis Notes
About 82.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 1.71. The entity had not issued any dividends in recent years. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Aclaris Therapeutics please contact the company at 484 324 7933 or go to https://www.aclaristx.com.Aclaris Therapeutics Investment Alerts
| Aclaris Therapeutics generated a negative expected return over the last 90 days | |
| Aclaris Therapeutics may become a speculative penny stock | |
| Aclaris Therapeutics has high historical volatility and very poor performance | |
| Aclaris Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 18.72 M. Net Loss for the year was (132.06 M) with loss before overhead, payroll, taxes, and interest of (30.32 M). | |
| Aclaris Therapeutics currently holds about 248.6 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Aclaris Therapeutics Earns Overweight Rating from Analysts at Cantor Fitzgerald |
Aclaris Therapeutics Upcoming and Recent Events
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Aclaris Largest EPS Surprises
Earnings surprises can significantly impact Aclaris Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-02-25 | 2020-12-31 | -0.27 | -0.3 | -0.03 | 11 | ||
2024-08-07 | 2024-06-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2024-05-07 | 2024-03-31 | -0.29 | -0.24 | 0.05 | 17 |
Aclaris Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Logos Global Management Lp | 2024-12-31 | 2.2 M | Millennium Management Llc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | Aldebaran Capital Llc | 2024-12-31 | 1 M | Two Sigma Advisers, Llc | 2024-12-31 | 977.4 K | Deutsche Bank Ag | 2024-12-31 | 923.3 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 908.8 K | Monashee Investment Management Llc | 2024-12-31 | 888.9 K | Bml Capital Management Llc | 2024-12-31 | 14.2 M | Adage Capital Partners Gp Llc | 2024-12-31 | 9.6 M |
Aclaris Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 183.85 M.Aclaris Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.75) | (0.79) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.85) | (0.89) |
Management Efficiency
Aclaris Therapeutics has return on total asset (ROA) of (0.1572) % which means that it has lost $0.1572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8446) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.63 in 2025. Return On Capital Employed is likely to drop to -0.79 in 2025. At this time, Aclaris Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 139.1 M in 2025, whereas Other Current Assets are likely to drop slightly above 7.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.01 | 1.91 | |
| Tangible Book Value Per Share | 2.01 | 1.91 | |
| Enterprise Value Over EBITDA | (3.23) | (3.39) | |
| Price Book Value Ratio | 1.23 | 0.70 | |
| Enterprise Value Multiple | (3.23) | (3.39) | |
| Price Fair Value | 1.23 | 0.70 | |
| Enterprise Value | 167.1 M | 327.7 M |
The strategic initiatives led by Aclaris Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 25th of March, Aclaris Therapeutics shows the Mean Deviation of 2.75, standard deviation of 3.71, and Risk Adjusted Performance of (0.19). Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aclaris Therapeutics standard deviation and value at risk to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 1.7 per share. Please also double-check Aclaris Therapeutics jensen alpha, which is currently at (0.79) to validate the company can sustain itself at a future point.Aclaris Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aclaris Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aclaris Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Aclaris Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aclaris Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aclaris Therapeutics Outstanding Bonds
Aclaris Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aclaris Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aclaris bonds can be classified according to their maturity, which is the date when Aclaris Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Aclaris Therapeutics Predictive Daily Indicators
Aclaris Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aclaris Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aclaris Therapeutics Forecast Models
Aclaris Therapeutics' time-series forecasting models are one of many Aclaris Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aclaris Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Aclaris Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Aclaris Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aclaris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aclaris Therapeutics. By using and applying Aclaris Stock analysis, traders can create a robust methodology for identifying Aclaris entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (7.05) | (7.41) | |
| Operating Profit Margin | (7.58) | (7.96) | |
| Net Loss | (7.05) | (7.41) | |
| Gross Profit Margin | 0.85 | 0.89 |
Current Aclaris Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aclaris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aclaris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 10.0 | Strong Buy | 7 | Odds |
Most Aclaris analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aclaris stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aclaris Therapeutics, talking to its executives and customers, or listening to Aclaris conference calls.
Aclaris Stock Analysis Indicators
Aclaris Therapeutics stock analysis indicators help investors evaluate how Aclaris Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aclaris Therapeutics shares will generate the highest return on investment. By understating and applying Aclaris Therapeutics stock analysis, traders can identify Aclaris Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 39.9 M | |
| Common Stock Shares Outstanding | 77.3 M | |
| Total Stockholder Equity | 155.6 M | |
| Property Plant And Equipment Net | 1 M | |
| Cash And Short Term Investments | 113.6 M | |
| Cash | 24.6 M | |
| Accounts Payable | 4.7 M | |
| Net Debt | -24.6 M | |
| 50 Day M A | 2.1476 | |
| Total Current Liabilities | 31.6 M | |
| Other Operating Expenses | 160.7 M | |
| Non Current Assets Total | 94.4 M | |
| Non Currrent Assets Other | 93.4 M | |
| Stock Based Compensation | 10.9 M |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.